Neopharmed Gentili, company owned by Ardian and the Del Bono family, acquires MDM
Milan, 31 October 2019. Neopharmed Gentili, a leading Italian pharmaceutical company active in the marketing of high-value therapeutic solutions controlled by Ardian and the Del Bono family, acquired 100% of MDM, a pharmaceutical company based in Monza active in the distribution of pharmaceuticals, nutraceuticals and medical devices for neurology and orthopedics.
With over 20 years of experience, MDM has a product portfolio complementary to Neopharmed’s, including several reference drugs for the treatment of neurological and osteoarticular disorders. Thanks to this acquisition, Neopharmed will consolidate its presence in the Italian market and expand its offering in highly strategic therapeutic areas.
Neopharmed has a proven track record in creating value through partnerships and acquisitions. This transaction perfectly fits with the strategy addressing both organic and external growth opportunities pursued by the Del Bono Family and Ardian since deal inception in November 2018. This partnership aims at establishing Neopharmed as one of the leaders in its market segment and at expanding the Group’s presence in adjacent therapeutic areas with high growth potential and undisputed strategic value.
Alessandro Del Bono, shareholder, Chairman and CEO of Neopharmed, stated: “I am particularly pleased to announce that MDM joined our Group. It is a highly strategic transaction and I would like to thank the Trognoni Family and the Monico Family, whose collaboration was pivotal to the successful completion of this acquisition. Furthermore, I am very happy to have Mr. Antonio Maggi, CEO of MDM, within our team. Thanks to his skills and experience, he will positively contribute to the Group’s future development. This transaction confirms Neopharmed’s growth strategy aimed at positioning itself among the main Italian pharmaceutical players”.
Established in 2009 within Mediolanum Farmaceutici, group founded in 1972 and still controlled by the Del Bono family, Neopharmed Gentili is a company specialized in the distribution of pharmaceutical products on the Italian market. Headquartered in Milan and led by Alessandro Del Bono, the company is one of the reference players in the Italian market, especially in the cardiovascular therapeutic area.
Over the years, Neopharmed has closed different partnerships and acquisition agreements which have positively contributed to the growth of the company and the diversification of its product portfolio among several therapeutic areas.
Neopharmed Gentili can leverage on a widespread presence on the Italian market, thanks to its 380 employees able to provide medicians with high level scientific support.
Ardian is a world-leading private investment house with US$96bn of assets under management. The company, which is majority-owned by its employees, keeps entrepreneurship at its heart and focuses on delivering excellent investment performance to its global investor base.
Through its commitment to shared outcomes for all stakeholders, Ardian’s activities fuel individual, corporate and economic growth around the world.
Holding close its core values of excellence, loyalty and entrepreneurship, Ardian maintains a truly global network, with more than 640 employees working from fifteen offices across Europe (Frankfurt, Jersey, London, Luxembourg, Madrid, Milan, Paris and Zurich), the Americas (New York, San Francisco and Santiago) and Asia (Beijing, Singapore, Tokyo and Seoul). It manages funds on behalf of more than 970 clients through five pillars of investment expertise: Fund of Funds, Direct Funds, Infrastructure, Real Estate and Private Debt.
Value Relations Angela Del Giudice
Mobile: +39 392 68 58 392